Richardson Electronics, Ltd. — Q2 FY2024 Form 10-Q
Reporting period: Quarter and six months ended December 2, 2023. The quarter comprised 13 weeks, as did the prior-year quarter; the six-month period comprised 27 weeks versus 26 weeks in the prior-year period. Financial amounts below are in millions of dollars unless stated otherwise.
Business context
Richardson Electronics supplies engineered solutions and products across four reportable segments: Power and Microwave Technologies (PMT), Green Energy Solutions (GES), Canvys customized displays, and Healthcare diagnostic-imaging parts and services. It serves a range of industrial, energy, medical, communications, and other markets.
Financial results and position
| Metric | Q2 FY2024 | Q2 FY2023 | Six months FY2024 | Six months FY2023 |
|---|---|---|---|---|
| Net sales | $44.1 | $65.9 | $96.7 | $133.5 |
| Gross profit / margin | $12.5 / 28.4% | $21.9 / 33.2% | $29.8 / 30.8% | $44.9 / 33.6% |
| SG&A | $14.5 | $14.7 | $30.3 | $28.9 |
| Operating income (loss) | $(2.0) | $7.2 | $(0.5) | $16.0 |
| Net income (loss) | $(1.8) | $5.5 | $(0.6) | $11.9 |
| Diluted EPS, common shares | $(0.13) | $0.39 | $(0.04) | $0.83 |
For the six months, operating cash flow was $1.8 million, capital expenditures were $2.7 million, and cash dividends paid were $1.7 million. Cash declined by $2.2 million from May 27, 2023, to $22.8 million at December 2, 2023. Inventory was $117.0 million, up from $110.4 million. Total liabilities were $37.8 million and stockholders’ equity was $158.6 million. No borrowings were outstanding on the $30 million revolving credit facility; the company reported compliance with its financial covenants. The facility matures March 20, 2026.
Common and Class B dividends for the six-month period were $0.12 and $0.108 per share, respectively. Management said existing liquidity, including cash and expected operating cash flows, should cover known working-capital and capital needs for at least the next 12 months.
Material changes and segment performance
Q2 sales fell 33.0% year over year; six-month sales fell 27.5%. Operating and net results moved from profit to loss in both comparisons. Gross margin declined in both periods, while SG&A was nearly flat in Q2 and increased for the six months; as a share of sales, SG&A rose to 32.8% in Q2 and 31.3% for the six months.
| Segment | Q2 sales change | Six-month sales change | Management’s cited drivers |
|---|---|---|---|
| PMT | -22.9% | -22.0% | Cyclical downturn in semiconductor wafer-fabrication markets; unfavorable product mix and manufacturing under-absorption pressured margins. |
| GES | -78.8% | -66.3% | Lower wind-turbine battery-module shipments and completion of Phase I of an EV locomotive prototype project; project-based sales are variable. |
| Canvys | -27.7% | -16.2% | Lower North American sales; improved product mix and lower freight costs supported margins. |
| Healthcare | -0.3% | -11.8% | Lower equipment sales in Q2 were partly offset by parts and CT tube sales; six-month sales declined in parts and equipment. Manufacturing under-absorption and component scrap weighed on margins. |
Outlook, risks, and notable items
No quantified company-wide revenue or earnings guidance is provided in the filing. Management expects Phase II of the EV locomotive prototype project to begin in Q2 FY2025. It cautions that results for the first six months are not necessarily indicative of full-year results.
Risks highlighted include global economic conditions, foreign-exchange fluctuations, labor and political conditions, disruption related to Russia’s invasion of Ukraine and sanctions, and the company’s ability to manage growth. The company also identifies U.S. tariffs of 25% on certain China-manufactured imports as a potential pressure on sales and margins if costs cannot be passed through or higher prices reduce demand. It does not use derivatives to manage foreign-currency exposure. Management reported no material change to previously disclosed risk factors, no material control changes, and effective disclosure controls.
Management attributed the margin decline mainly to product mix and manufacturing under-absorption in PMT, GES, and Healthcare; higher Healthcare component scrap also affected the six-month comparison. Foreign-exchange losses were $0.3 million in Q2 and $0.2 million for the six months. The filing reports no outstanding uncertain tax positions. Inventory reserves were approximately $5.9 million, unchanged from fiscal year-end; management said it did not then anticipate material future inventory write-down risks, while noting that changed demand or market conditions could require additional provisions.
Key facts for investors to verify
- Whether the sharp sales contraction, particularly in GES and PMT, continues or reverses, and how project timing affects GES comparisons.
- Whether gross margins recover as product mix and manufacturing utilization change, and whether inventory levels and reserves remain appropriate.
- Whether operating cash generation can support working capital, capital expenditures, dividends, and the company’s stated liquidity outlook.
- Exposure to semiconductor-market cyclicality, tariffs on China-origin products, foreign-exchange movements, and the terms and covenant headroom of the revolving facility.
- The timing and expected commercial or financial contribution of GES’s planned EV locomotive prototype Phase II.